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Abstract
Purpose The extent of neovascularization determines the clin-
ical outcome of coronary artery disease and other occlusive
cardiovascular disorders. Monitoring of neovascularization is
therefore highly important. This review article will elaborately
discuss preclinical studies aimed at validating new nuclear
angiogenesis and arteriogenesis tracers. Additionally, we will
briefly address possible obstacles that should be considered
when designing an arteriogenesis radiotracer.
Methods A structured medline search was the base of this
review, which gives an overview on different radiopharma-
ceuticals that have been evaluated in preclinical models.
Results Neovascularization is a collective term used to indicate
different processes such as angiogenesis and arteriogenesis.
However, while it is assumed that sensitive detection through
nuclear imaging will facilitate translation of successful thera-
peutic interventions in preclinical models to the bedside, we
still lack specific tracers for neovascularization imaging. Most
nuclear imaging research to date has focused on angiogenesis,
leaving nuclear arteriogenesis imaging largely overlooked.
Conclusion Although angiogenesis is the process which is
best understood, there is no scarcity in theoretical targets for
arteriogenesis imaging.
Keywords Radiotracer imaging . Angiogenesis .
Arteriogenesis . Myocardial infarction . Peripheral vascular
disease
Introduction
Molecular imaging enables the study of molecular and cellular
processes in vivo [1]. Within this field, several noninvasive
imaging techniques such as Magnetic Resonance imaging
(MRI), Computed Tomography (CT), Optical Imaging (OI),
Positron Emission Tomography (PET) and Single Photon
Emission Computed Tomography (SPECT) are distinguished.
The latter two are the most established techniques for targeting
ongoing biochemical processes and are based on the detection
of injected radiolabeled probes. While the spatial resolution of
MRI and CT is higher, the detection sensitivity of PET and
SPECT is within the picomolar or nanomolar range and there-
fore significantly higher than for MRI and CT [2, 3]. Spatial
resolution and detection sensitivity are two performance char-
acteristics that play an important role in molecular imaging
research using SPECT and PET tracers. Clinical gamma cam-
eras can provide a tomographic resolution of about 10 mm
while preclinical devices currently reach submillimeter reso-
lutions using a specialized multipinhole geometry [2, 4]. The
difference between clinical and preclinical PET devices is
smaller. While preclinical scanners reach spatial resolutions
of 1–2 mm, clinical scanners operate within the range of 4–
6 mm. The application for dedicated small animal SPECTand
PET imaging modalities in preclinical models is highly valu-
able, as it has a great scope for noninvasive studying of
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dynamic biological processes at the molecular and cellular
level [2]. Because of the high societal burden of disease, the
cardiovascular system is a well-recognized target for molecu-
lar imaging. Longitudinal studies, monitoring cardiac function
[5], imaging of atherosclerosis [6, 7], tissue viability and per-
fusion [8] and neovascularization [9, 10] are among the most
studied cardiovascular areas. Molecular imaging of neovascu-
larization has received a significant amount of attention as we
still lack sensitive detection of neovascularization. It is as-
sumed that such sensitive detection will facilitate translation
of successful therapeutic interventions in preclinical models to
the bedside [8, 11]. Neovascularization can be divided in three
distinct processes, vasculogenesis, arteriogenesis and angio-
genesis [12], and its extent determines the clinical outcome of
coronary artery disease and other occlusive cardiovascular
disorders. Vasculogenesis refers to the in situ formation of
blood vessels from circulating endothelial progenitor cells.
Despite the importance of this process during embryogenesis,
its further discussion is beyond the scope of this review. The
term arteriogenesis describes the enlargement of pre-existing
arteriolar anastomoses into large collaterals in response to en-
hanced fluid shear stress [13]. Angiogenesis is an ischemia
driven process that represents the sprouting of new capillaries
from existing microvasculature [9].
Arteriogenesis is the most important mechanism in the func-
tional replacement of an occluded artery in peripheral vascular
disease (PVD) [13, 14], but the enlargement of coronary col-
lateral arteries in obstructive coronary artery disease is also well
described [15]. Angiogenesis is associated with postinfarct re-
modeling and has important implications for the prognosis fol-
lowing myocardial infarction (MI) [16], whereas its role in
perfusion recovery in PVD is of less importance [13]. In this
review, we will focus on SPECT- and PET-based neovascular-
ization studies in the context of MI and peripheral vascular
disease (PVD). As will become apparent from this review, ex-
tensive research has been conducted concerning radiotracer im-
aging of angiogenesis, while arteriogenesis radiotracer imaging
is scarce and largely overlooked. Despite large parts of the
pathways involved in arteriogenesis being unraveled, radio-
tracers specifically targeting this multifactorial process are yet
to be developed. Alluding to the inferior amount of work being
published on radiotracer imaging of arteriogenesis, we will
briefly discuss the possible hurdles which have to be overcome
in order to develop a nuclear arteriogenesis tracer.
Perfusion tracers in neovascularization research
Although perfusion radiotracers do not directly target angio-
genesis or arteriogenesis, they are used as indicators for areas
of (mainly myocardial) ischemia, thereby often serving as a
contrast in radiotracer-guided neovascularization research.
The distribution kinetics of these tracers are therefore highly
important for imaging of neovascularization. Perfusion tracers
are even used as surrogate markers for neovascularization in
pre-clinical research (BRadiotracer imaging of arteriogenesis^
section). Accordingly, this section serves as a brief introduc-
tion into the uptake mechanisms, kinetics, and application of
the most common SPECT and PET perfusion tracers.
Frequently employed perfusion tracers for SPECT are
Thallium-201 (201Tl), Technetium-99 m (99mTc)-sestamibi,
99mTc-tetrofosmin and 99mTc-pyrophosphate, while for PET,
Oxygen-15 (15O)-water, N-13 (13N)-ammonia, Rubidium-82
(82Rb) and the more recently developed Fluorine-18 (18F)-
labeled Flurpir idaz (Lantheus Medical Imaging,
Massachusetts, USA) are the most common perfusion tracers.
201Tl is taken up in viable cells via the sodium-potassium
pump as it has properties similar to potassium [17]. However,
while 201Tl has successfully been used in cardiac perfusion
imaging [18] and in skeletal muscle perfusion imaging in
PVD patients [19–22], 99mTc-labeled perfusion tracers have
largely replaced the use of 201Tl. Beside the considerably low-
er radiation exposure (6 vs. 28 millisievert) 99mTc-labeled
tracers offer more advantages compared to 201Tl, the most
essential being the shorter half-life (6 h for 99mTc compared
to 73 h for 201Tl), allowing for injection of higher doses, in
combination with the higher energy level at which 99mTc emits
gamma rays [140 k electronvolt (keV) compared to 78 keV for
201Tl], which results in less scatter and attenuation. Together,
these advantages culminate in improved imaging [23].
One 99mTc-labeled compound in particular, 99mTc-
sestamibi, is omnipresent in clinical cardiology [24] and has
also been incorporated in several studies examining lower-
extremity perfusion in PVD [25–27]. 99mTc-sestamibi is a li-
pophilic, cationic complex of six isonitriles [23]. Like 201Tl,
uptake of 99mTc-sestamibi after intravenous injection is pro-
portional to blood flow [28]. Cellular uptake and retention of
99mTc-sestamibi are dependent on mitochondrial and plasma
membrane potentials [29–31]. After uptake, the compound
resides in myocardial cells after initial extraction and demon-
strates minimal delayed redistribution [32–34]. In a case re-
port, the merit of clinical application of 99mTc-sestamibi over
Doppler ultrasound in PVD patients has already been reported
on the basis of improved sensitivity in detecting differences in
detecting differences of resting perfusion between the lower
extremities [35]. 99mTc-tetrofosmin is an alternative lipophilic
cationic complex with comparable uptake characteristics and
similar widespread use in myocardial perfusion imaging [24].
However, the hepatobiliary clearance of 99mTc-tetrofosmin is
reported to be slightly faster than for 99mTc-sestamibi [23].
Recently, Stacy et al. showed preliminary data and indicated
that SPECT/CT using 99mTc-tetrofosmin has the potential to
assess regional differences in lower-extremity perfusion in
PVD patients. Furthermore, 99mTc-pyrophosphate, binding
to hydroxyapatite crystals in damaged myocytes, has been
frequently employed in clinical practice to identify fresh
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myocardial infarctions since its introduction in 1974 [36, 37].
Additionally, 99mTc-pyrophosphate has been successfully
used to estimate the ischemic skeletal muscle mass in a canine
ischemia-reperfusion skeletal muscle model [38] and in PVD
patients [39].
Themost prominent PET perfusion tracers are 15O-water and
13N-ammonia. Both tracers have a short half-life (2.4 min and
9.8 min respectively) requiring an on-site cyclotron to enable
application, thereby limiting the use of these tracers to a few
centers [40]. Myocardial blood flow acquired with 15O-water
and 13N-ammonia have been widely validated against indepen-
dent microsphere blood flowmeasurements in animals and have
yielded highly reproducible values over a range of 0.5 to 5.0 ml/
g/min. [40–42] 15O-water, diffusing freely into the tissue, is also
frequently implemented in PVD patient studies [43–47]. The
characteristics of 15O-water make the tracer suitable for repeated
measurements during a single visit, measurements at rest and
during exercise or during vasodilator stress. An 15O-water rest-
stress PET study found significantly lower calf muscle flow
reserve in PVD patients compared to healthy control subjects,
and these measurements correlated with thermodilution-derived
flow reserve values [45]. Furthermore, a study by Scremin et al.
showed that accurate muscle blood flow detection by 15O PET
in legs with severe ischemia could add valuable information
about skeletal muscle viability in the residual limb when decid-
ing the level of an amputation [46]. However, despite its fre-
quent application, 15O-water images of the myocardium are
commonly of lower count density due to subtraction of the
blood pool, rapid clearance of 15O-water and its short half-life.
Therefore, 15O-water images are not suitable for the visual anal-
ysis of myocardial radiotracer uptake, and thus are not used
clinically for coronary artery disease detection [40, 48]. 13N-
ammonia is cleared rapidly from the circulation and is primarily
taken up by the myocardium, brain, liver, kidneys and the pitu-
itary gland [49, 50]. In both myocardium and brain, 13N-ammo-
nia is removed from the blood by first-pass extraction (approx-
imately 80 %) and is metabolically trapped within the tissues by
incorporation into the cellular pool of amino acids, mainly as
glutamine [50–52]. The high first pass extraction, in combina-
tion with a sufficiently long half-life, allow high count images to
be acquired. Hence, flow-limiting coronary artery disease can be
visualized on stress-rest images using 13N-ammonia [53, 54].
While 13N-ammonia PET is frequently used to measure myo-
cardial perfusion, its application for measuring skeletal muscle
perfusion is rare, though not absent. In a patient with a right-
sided static tremor, higher uptake of 13N-ammonia was found in
the muscles of the right leg, which was related to increased
perfusion produced by continuous exercise of the muscles in-
volved in the tremor [55]. Furthermore, 13N-ammonia PETwas
successfully used to measure local perfusion in the legs of pa-
tients with painful diabetic neuropathy [56].
82Rb, a functional potassium analog, is an alternative ra-
dioactive tracer of myocardial perfusion that can be imaged
with PET [24, 40]. Its diagnostic and prognostic performances
appear comparable to conventional blood flow SPECT imag-
ing [57, 58]. Although 82Rb can be eluted from a commercial-
ly available Strontium-82 generator on site [40], a major lim-
itation is its ultrashort half-life (76 s), which limits its use to
pharmacological stress perfusion imaging [24].
A promising 18F-labeled perfusion tracer was added to the
available PET perfusion tracers almost a decade ago in the form
of Flurpiridaz (initially evaluated as: BMS-747158-02; Lantheus
Medical Imaging, Massachussets USA). Flurpiridaz is an analog
of the insecticide pyridine, which binds to the mitochondrial
complex I of the electron transport chain with a very high affinity
[40, 59, 60]. The radiotracer is rapidly cleared from the blood (in
under 5 min) and displays stable uptake in the healthy and in-
farcted myocardium up to 40 min. Furthermore, 18F-Flurpiridaz
has a high first-pass extraction fraction above 90 % (which is
preserved at high flow rates) and a very slow wash out [40].
These favorable properties in combination with its half-life of
109 min result in high count images of high diagnostic quality
for the detection of perfusion deficits underlying coronary artery
disease (CAD) [40, 61, 62]. 18F-Flurpiridaz myocardial blood
flow PET imaging was validated using radioactive microspheres
in a pig model [40, 63]. Moreover, positive results from phase 2
human studies have been published [61]. The high extraction
fraction of 18F-Flurpiridaz may offer an advantage for evaluating
lower-extremity skeletal muscle blood flow. However, so far
there are no studies that assessed the potential of 18F-
Flurpiridaz in the setting of PVD.
Radiotracer imaging of angiogenesis
Angiogenesis
The formation of new capillary arteries from pre-existing mi-
crovasculature is termed angiogenesis. Angiogenesis is a dy-
namic process involving endothelial proliferation and differ-
entiation which is mainly triggered by tissue ischemia or hyp-
oxia. During this process, new capillaries form around ische-
mic tissue zones, as they occur in MI, stroke, and PVD [64,
65]. Upon development of tissue ischemia, transcription fac-
tors such as hypoxia inducible factor 1α (HIF-1α) and inflam-
matory mediators are released locally resulting in vasodila-
tion, enhanced vascular permeability, and accumulation of
monocytes and macrophages, which in turn secrete more
growth factors and inflammatory mediators [65, 66]. These
inflammatory cells facilitate degradation of the basal mem-
brane of the parent artery and the surrounding extracellular
matrix (ECM) through the release of matrix metalloprotein-
ases (MMPs). Following ECM degradation, endothelial cells
migrate and proliferate down a hypoxia-sensitized chemotac-
tic gradient of various growth factors to form a new capillary
vessel with a lumen [65]. The role of integrins in this part of
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the angiogenic process is of paramount importance, as
integrins are the principle adhesion receptors used by endo-
thelial cells to interact with their extracellular microenviron-
ment [67]. The subsequent formation of a functioning vascu-
lature requires the orchestrated interaction of endothelial cells,
the extracellular matrix, and surrounding cells such as
pericytes and smooth muscle cells [65, 68]. This sprouting
process iterates until proangiogenic signals abate, and quies-
cence is re-established [69] (Fig. 1).
Angiogenesis is a multistep process orchestrated by a mul-
titude of angiogenic factors and inhibitors, which offer a wide
range of targets for therapeutic interventions and imaging [9,
68]. Because of its important role in the (partial) restoration of
tissue perfusion in the ischemic area, angiogenesis stimulating
therapy is an intensely studied subject in cardiovascular re-
search. Nevertheless, while results from animal studies have
been encouraging [70–74], the results obtained during clinical
studies have not been convincing [75–78]. Plausible explana-
tions for the latter are ineffective growth factor delivery, irre-
producible readout parameters, and an unresponsive patient
population [79]. However, the most important feature in a
therapeutic intervention study is its ability to accurately mon-
itor the targeted process. Current clinical readout parameters
such as peak walking distance in PVD trials [80] and the
exercise tolerance test in coronary artery disease trials [78]
are not sufficiently sensitive and reproducible. Surely, perfu-
sion imaging through MRI, SPECT and PET imaging can be
used to indicate enhanced perfusion of the ischemic tissue.
However, it often takes several months before improvement
becomes apparent [8]. In order to facilitate early diagnosis and
early treatment for patients with ischemic cardiovascular dis-
ease specific and sensitive non-invasive tracers for neovascu-
larization will be required.
Main targets for targeted radiotracer imaging
of angiogenesis in myocardial ischemia
The main targets for nuclear angiogenesis imaging in animal
models of MI are the αvβ3 integrin and the vascular endothe-
lial growth factor (VEGF)-receptor, while CD105 (endoglin)
and CD13 (aminopeptidase-N) were also successfully used
(Table 1).
Integrins are transmembrane receptors that contribute to the
angiogenic process through increased signal transduction as
well as modulation of cell adhesion to the extracellular matrix
[47, 67, 95]. The αvβ3 integrin (also termed vitronectin recep-
tor) is the most abundant integrin expressed on the surface of
proliferating endothelial cells and has been implicated in cell
migration and cell survival signaling. Further, the αvβ3
integrin is minimally expressed on normal quiescent endothe-
lial cells [96]. These properties have made the αvβ3 integrin a
target of choice for the imaging of angiogenesis. The arginine-
glycine-aspartic acid (RGD) peptide, naturally present in ex-
tracellular matrix proteins, was found to be highly selective
for the αvβ3 integrin. The discovery of the RGD sequence has
marked the starting point for the development of probes
targeting the αvβ3 integrin [9, 96]. RGD peptides evolved
from linear peptides with low selectivity and biostability to
constructs with better pharmacokinetics (through attachment
of carbohydrates, charged amino acids and polyethylene gly-
col groups) and optimized binding characteristics (through
multimerization) [9, 96].
Currently, a large variety of RGD peptides have been de-
veloped that are suited for radiolabeling into SPECT or PET
tracers for non-invasive imaging of angiogenesis. Pre-
Fig. 1 Mechanism of
angiogenesis. Capillary sprouting
is guided into the ischemic area
down a chemotactic gradient of
growth factors. Modified from
Carmeliet, 2000, Nature
Medicine [12]
Table 1 Radiotracers for myocardial angiogenesis imaging in pre-
clinical studies
Myocardial angiogenesis




111In-RP748 SPECT [16, 85, 86]
123I-gluco-RGD SPECT [87]
18F-galacto-RGD PET [88, 89]
18F-AlF-NOTA-PRGD2 PET [90]
68Ga-NOTA-RGD PET [91, 92]
68Ga-NODAGA-RGD PET [89]
68Ga-TRAP(RGD)3 PET [89]
CD13 111In-DTPA-cNGR SPECT [8]
VEGF receptor 64Cu-DOTA-VEGF121 PET [93]
CD105 64Cu-NOTA-TRC105 PET [94]
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clinically, these tracers have been tested in animal models for
MI, with and without reperfusion and in the presence of pro-
angiogenic growth factors, and in hind limb ischemia.
Enhanced angiogenesis post-MI has been indicated by several
groups using Technetium-99 m (99mTc)-labeled RGD pep-
tides. 99mTc-NC100692 (maraciclatide®) is a technetium-
labeled cyclic RGD peptide that has been used in a variety
of SPECT studies to non-invasively assess angiogenesis [97].
This compound has a high affinity for the αvβ3 integrin, is
metabolically stable, and has a biodistribution and kinetics
that are favorable for SPECT imaging. SPECT imaging of
99mTc-NC100692 was successfully used to indicate post-MI
angiogenesis hypoperfused (indicated by 201Tl) myocardial
regions of matrix-metalloproteinase-9 (MMP-9) null mice
compared to wild-type mice [83]. In rats, SPECT imaging of
99mTc-NC100692 was used to indicate ongoing angiogenesis
in the peri-infarct region after MI [81] and in reperfused is-
chemic myocardium [82]. Furthermore, 99mTc-RAFT-RGD, a
different RGD-based tracer for targetingαvβ3 integrin expres-
sion in vivo, was used in a rat model of reperfused ischemic
myocardium. SPECT imaging was used to show enhanced
99mTc-RAFT-RGD, but not 99mTc-RAFT-RAD (negative con-
trol), uptake in the infarct and peri-infarct zone 14 days after
reperfusion [84]. Additionally, specific binding of 99mTc-
RAFT-RGD to the αvβ3 integrin was shown in human micro-
vascular endothelial cells, as the presence of an excess of
unlabeled RGD resulted in a significant inhibition of 99mTc-
RAFT-RGD binding.
The suitability of the αvβ3 integrin as a target for radiotrac-
er imaging of angiogenesis was further established by studies
that employed the indium-111 (111In)-labeled RP748 (also
named quinolone). 111In-RP748 is an αvβ3 integrin binding
small molecule that specifically binds to activated endothelial
cells in vitro and vivo [98]. This SPECT radiotracer has sub-
sequently been assessed in rat [16, 85, 86] and canine [16, 86]
models of MI in both early (acute) and late (3 weeks) time
points after induction of MI. Binding specificity of 111In-
RP748 was shown by a direct comparison with the control
compound 111In-RP790 having similar chemical structure, al-
though no in vitro specificity for αvβ3-integrin. SPECT im-
aging revealed no uptake of 111In-RP790 in hypoxic or infarct
areas [16, 86].
Furthermore, in a swine model of hibernating myocardium,
SPECT imaging revealed enhanced Iodine-123 (123I)-gluco-
RGD uptake in areas corresponding to 201Tl defects in animals
that received an endomyocardial injection of VEGF, com-
pared to animals that received a saline control injection. No
uptake of an 123I-labeled control peptide was seen in the heart
of a control animal [87].
Despite the variety in SPECT radiotracers for angiogenesis,
PET radiotracers for angiogenesis have actually been investi-
gated more frequently, with results that are very similar to
studies that use SPECT imaging in preclinical models of
cardiac angiogenesis. Tracers that have been used include
18F-galacto-RGD [88, 89], 18F-AlF-NOTA-PRGD2 [90],
68Ga-NOTA-RGD [91, 92], 68Ga-NODAGA-RGD [89], and
68Ga-TRAP(RGD)3 [89]. Remarkably, in some studies, the
uptake of RGD-based PET tracers was enhanced up to 4
[90] or even 6 [88] months after the angiogenesis stimulating
intervention. Specificity of uptake was shown either by inhi-
bition of binding with a specific non-radiolabeled αvβ3
integrin antagonist [88] or by co-incident and co-localized
endothelial integrin markers such as CD31 or CD61 (β3)
[89, 90, 92].
Together with the αvβ3 integrin, the RGD peptide forms a
reliable axis for targeted radiotracer imaging of angiogenesis.
However, despite the promising results obtained in pre-
clinical studies, the application of RGD-based radiotracers
for angiogenesis imaging in the context of myocardial ische-
mia or PVD in the clinic is modest to say the least. Instead
radiotracer imaging of angiogenesis in patients so far has
largely focused on imaging of tumor angiogenesis. As in
pre-clinical research, the main target for imaging has been
the αvβ3 integrin through various radiolabeled RGD peptides
[99–106], while the VEGF receptor [107], prostate-specific
membrane antigen (PSMA) [108], and the extra domain B
of fibronectin [109] have also received attention. To date, only
a few small studies in MI patients have been performed, all
using the αvβ3 integrin as a target for angiogenesis imaging
[110–112] (Table 2).
Makowski et al. used PET/CT imaging to target the αvβ3
integrin with 18F-galacto-RGD in an MI patient, and found
enhanced uptake in infarcted area (defined by the extent of
delayed enhancement MRI and decreased 13N-ammonia myo-
cardial blood flow) 2 weeks after MI. The feasibility of clin-
ical angiogenesis imaging through targeting the αvβ3 integrin
was further shown in studies by Mozid et al. [111] and Sun
et al. [112]. Mozid and co-workers applied an intracoronary
injection of granulocyte colony-stimulating factor mobilized
bone-marrow stem cells in patients with chronic ischemic
heart failure. Using 99mTc-NC100692 SPECT imaging they
found baseline (day 0) uptake in all heart failure patients with
no uptake seen in control patients. This suggests persistent
angiogenesis in patients with chronic heart failure and remote
MI, which is in line with the preclinical finding of enhanced
Table 2 Radiotracers for myocardial angiogenesis imaging in clinical
studies
Myocardial angiogenesis





Eur J Nucl Med Mol Imaging (2016) 43:2433–2447 2437
uptake long after the ischemic incident. Unfortunately, no
proof of concept was provided that therapy-induced neovas-
cularization can be picked up by RGD-based PET imaging in
a robust manner [111]. Sun and co-workers used 68Ga-
PRGD2 SPECT inMI and stroke patients and found enhanced
uptake in 20 out of 23MI patients and in eight out of 16 stroke
patients. Furthermore, higher uptake of 68Ga-PRGD2 was ob-
served 1–3 weeks after the onset of MI/stroke and correlated
well with the disease phase and severity [112].
Large volume patient studies employing RGD-based radio-
tracers for imaging of post-MI angiogenesis imaging are cur-
rently lacking, despite the fact that there is no scarcity in tracer
constructs. This begs the question if this is because of uncer-
tainty if targeted angiogenesis imaging has clinical benefit due
to unconvincing results in the small scale clinical studies, or
because there is lack of scientific interest in the absence of
approved therapeutic angiogenesis? The amount of pre-
clinical studies suggests there is no lack of scientific interest,
so it is assumed that the field is held up by a lack of therapeutic
programs.
Fortuitously, angiogenesis is hallmarked by the upregula-
tion of multiple biomarkers. Beside upregulation of the αvβ3
integrin, CD13, a membrane bound aminopeptidase, is also
upregulated on angiogenically active endothelial cells [113,
114]. CD13, expressed on active endothelial cells, can specif-
ically be targeted using an asparagine-glycine-arginine (NGR)
peptide motif. [114] Competition studies in tumor angiogen-
esis with the NGR and RGD motifs demonstrated a threefold
higher target homing ratio (tumor/control organ) for NGR
than for RGD [115]. In a recent study by our own group,
CD13 was targeted with a cyclic asparagine-glycine-arginine
(NGR) peptide, having a tenfold higher targeting efficacy than
the linear entity [116], which was coupled to 111In via a
diethylene triamine pentaacetic acid (DTPA) chelator. Dual
isotope SPECT imaging indicated significantly enhanced up-
take of 111In-DTPA-cNGRmainly in areas of 99mTc-sestamibi
absence (infarct region) [8]. Given the higher target homing
ratio compared to the RGD motif, it is interesting to speculate
that CD13 targeting through NGR-based tracers could lead to
better image quality and subsequently better possibilities for
clinical translation. However, studies comparing NGR and
RGD-based tracers in the same model have to be conducted
before such claims can be justified. Furthermore, to gain in-
sight into the true benefit of monitoring angiogenesis in com-
parison with traditional endpoints or indirect effects such as
clinical state, or tissue perfusion or function, large volume
patient studies have to be conducted.
Other targets for radiotracer imaging of angiogenesis
in myocardial ischemia
Although various angiogenesis stimulating factors exist,
VEGF is considered the most potent and predominant factor
[79, 95]. VEGF ligands, of which there are four known iso-
forms (A-D), are released in response to ischemia and mediate
their angiogenic effects by binding to specific VEGF receptors
(VEGFR-1, VEGFR-2 and VEGFR-3), leading to receptor
dimerization and subsequent intracellular signal transduction
via tyrosine kinases [117, 118]. The majority of VEGF-based
radiotracers have been evaluated in the context of tumor an-
giogenesis imaging. However, peripheral angiogenesis and
post MI angiogenesis have been examined as well.
In a rat MI model, increased myocardial uptake in infarcted
myocardium (visualized by 18F-FDG) of the PET radiotracer
Copper-64 (64Cu)-DOTA-VEGF121 was shown on day 3, 7
and 17 after induction of MI. Myocardial origin of the radio-
tracer signal was confirmed by CT co-registration and autora-
diography [93].
Among the targets that received less attention while being
successfully used for nuclear imaging of angiogenesis are
CD105, a 180 kDa disulfide-linked homodimeric transmem-
brane protein selectively expressed on the endothelial cells of
newly formed vessels [119–122], and CD13, a membrane
bound aminopeptidase found on activated endothelial cells
[113]. PET imaging of CD105 expression in a rat MI model
with 64Cu-labeled TRC105, an anti-CD105 monoclonal anti-
body, revealed significantly enhanced uptake in infarcted
myocardium (indicated by 18F-FDG) 3 days after surgically
induced MI compared to sham operated control animals.
These findings were supported by histology, indicating in-
creased CD105 expression following MI [94].
Radiotracer imaging of angiogenesis in peripheral
vascular disease
PVD is a progressive atherosclerotic process that results in
stenosis or occlusion of non-coronary blood vessels, most
frequently the iliac and femoral artery [47]. Progressive ische-
mia, present in PVD, can lead to intermittent claudication,
non-healing ulcers, limb amputation and in severe cases, death
[47, 123]. Despite the severity of this disease, a significant
proportion of individuals with PVD remain undiagnosed in
clinical practice [124].
Although angiogenesis might have less impact on perfu-
sion recovery in PVD than arteriogenesis, targeted nuclear
imaging of angiogenesis can provide valuable information of
the underlying pathophysiology associated with PVD.
Especially in combination with lower-extremity perfusion im-
aging, areas of ischemia can be identified that might have
remained unnoticed on MRI images or other techniques used
in present day clinical care (e.g. ankle-brachial index, duplex
ultrasound or CT angiography) [47].
In pre-clinical research, numerous hind-limb ischemia
models have been established in several laboratory animals
to mimic the situation of PVD and to study (stimulation of)
neovascularization [125]. Like in MI models, targeted
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imaging of angiogenesis in pre-clinical models of PVD has
mainly focused on the αvβ3 integrin and VEGF receptors
(Table 3).
The αvβ3 integrin
The majority of RGD-based radiotracers that have beenh de-
veloped have been tested in cardiac angiogenesis models.
However, among them, 99mTc-NC100692 [126, 127] and
68Ga-NOTA-RGD [128] have also been evaluated in preclin-
ical PVDmodels. Additionally, 125I-c(RGD(I)yV) [129] and a
bromine-76-labeled nanoprobe (76Br-Nanoprobe) [130] have
only been tested in a mouse model for PVD. Specific radio-
tracer uptake was concluded from the absence of uptake of a
scrambled control peptide [126, 129], inhibition of binding
using an excess of the non-radiolabeled tracer [128, 130] or
by co-localized binding of a fluorescent tracer analogue and
CD31 [127]. With the majority of studies only assessing ra-
diotracer uptake at relatively short time points after induction
of ischemia (i.e. up to 14 days) [127–130] and only one study
assessing uptake after 4 weeks [126], the possibility and ben-
efit of radiotracer guided imaging of neovascularization in
PVD models at later time points remains to be discovered.
Growth factor receptors
The involvement of numerous growth factors such as VEGF
and FGF in neovascularization has been described, and also in
PVD [135]. Growth factor functions are regulated in a com-
plex fashion with multiple feedback systems influencing
many cell types; hence, it is extremely difficult to elucidate
unique roles of each growth factor unless it is specific to a
single cell type [136]. Therefore, rather than targeting the
growth factor itself for molecular imaging, their most impor-
tant or abundant receptors have been used as targets, as these
are thought to be more specifically regulated during neovas-
cularization than their ligands. For example, the extracellular
matrix (ECM) serves as a reservoir for growth factors [137],
thereby forming a storage that can be tapped on demand.
Detecting the presence of growth factors by molecular imag-
ing could therefore be unrelated to active neovascularization.
As VEGF is one of the dominant growth factors inducing
angiogenesis, its functional receptor, VEGFR2 has been
targeted frequently for molecular imaging. Using VEGF121,
a natural splice variant of VEGF165 that lacks an ECM reser-
voir binding capacity [138], the VEGFR2 receptor can be
visualized in relationship to neovascularization events. In a
rabbit hind limb ischemia model, 10 days after arterial liga-
tion, uptake of 111In-VEGF121 was enhanced as shown by
SPECT imaging and post-mortem gamma counting [131].
Corresponding immunohistological findings of increased
VEGFR2 expression validated the principle. A similar finding
was reported using PET and 64Cu-labeled VEGF121 in a
mouse hindlimb ischemia study, where the level of uptake
correlated well with VEGFR2 protein levels in ligated and
control limbs in the presence and absence of exercise [132].
Other targets for radiotracer imaging of angiogenesis
in peripheral vascular disease
Other targets that were successfully used for nuclear imaging
of peripheral angiogenesis are CD105 and the natriuretic pep-
tide clearance receptor (NPR-C). Among the four natriuretic
peptide family members, all binding the NPR-C, atrial natri-
uretic peptide and C-type natriuretic peptide have been dem-
onstrated to suppress VEGF signaling and to attenuate angio-
genesis [139–142]. Liu et al. developed a C-type atrial natri-
uretic factor (CANF)-conjugated comblike nanoprobe that
was labeled with 64Cu. In a mouse model of hind limb ische-
mia PET imaging of 64Cu-DOTA-CANF-comb showed a sig-
nificantly higher uptake in the ischemic hind limb compared
to the nonischemic control limb 7 days after induction of is-
chemia. These results were supported by immunohistochem-
ical findings of NPR-C upregulation with colocalization in
endothelial (via PECAM-1 staining) and smooth muscle cells
(via α-actin staining) [133].
Furthermore, the PET tracer 64Cu-NOTA-TRC105 was
used to assess the response to pravastatin treatment in a mouse
ischemic hind limb model. Pravastatin is a member of the
statin group of cholesterol-lowering drugs that is also known
to stimulate NO-mediated angiogenesis. Significantly in-
creased radiotracer uptake in the ischemic hind limb compared
to the control hind limb was shown at day 3, 10, 17 and 24
after induction of hind limb ischemia in the pravastatin treated
group with CD31/CD105 co-immunostaining validating the
radiotracer uptake [134].
In sharp contrast to targeted neovascularization imaging in
cancer patients and to a lesser extent inMI patients, radiotracer
imaging in PVD patients is based entirely on the use of per-
fusion tracers rather than on targeted imaging of
Table 3 Radiotracers for peripheral angiogenesis imaging in pre-
clinical studies
Peripheral angiogenesis
Biological target Tracer Modality Reference(s)
Avβ3 integrin




VEGF receptor 111In-VEGF121 SPECT [131]
64Cu-VEGF121 PET [132]
NPR-C 64Cu-DOTA-CANF-comb PET [133]
CD105 64Cu-NOTA-TRC105 PET [134]
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neovascularization. Although specific angiogenesis tracers are
readily available, it would be more appropriate and helpful to
monitor arteriogenesis, as it is by far the most efficient adap-
tive mechanism of survival for ischemic limbs [143].
However, in the absence of specific arteriogenesis tracers,
perfusion tracers are currently used for diagnosis and moni-
toring of perfusion recovery. In order to improve diagnosis
and therapy monitoring in PVD, but also in MI patients, the
development of specific arteriogenesis tracers is warranted.
Radiotracer imaging of arteriogenesis
Arteriogenesis
Since the first observations by Fulton in 1964 [144], our
knowledge about arteriogenesis and its underlying cellular
and molecular mechanisms has increased vastly, though the
fundamental event that initiates mitogenic stimulation has not
been unraveled as of today.
The initiation of arteriogenesis is, in sharp contrast to an-
giogenesis, independent of ischemia and instead relies on
physical factors (Figs. 2 and 3). Following the occlusion of a
conductance artery, it is generally accepted that the
arteriogenic process is initiated in the pre-existing collaterals
that circumvent the obstruction by deformation of the endo-
thelial cells as a consequence of increased pulsatile fluid shear
stress. Initially, these pre-existing collateral arteries are inca-
pable of conducting the mandatory blood supply to the tissue
that is situated distally of the occlusion. In order to cope with
the increased perfusion pressure, diametrical growth and ar-
tery maturation of the pre-existing collateral artery are re-
quired. Successful maturation into a conductance artery relies
on the creation of a transient inflammatory environment.
Increased expression of adhesion molecules, cytokines and
growth factors by the endothelium in response to increased
shear stress hallmark the inaugural events in a complex cas-
cade [147]. Subsequently, circulating monocytes attach to the
endothelium, migrate to the peri-collateral space, and differ-
entiate into macrophages [148, 149]. The inflammatory reac-
tion that ensues is vital to arteriogenesis and driven by the
secretion of growth factors and cytokines from endothelial
cells, smooth muscle cells, monocytes, and macrophages.
Among these secreted factors are monocyte chemotactic pro-
tein 1 (MCP1), which induces the attraction of more mono-
cytes; tumor necrosis factor α (TNFα), which provides the
inflammatory environment in which collateral vessels devel-
op; and MMPs that control the digestion of the internal elastic
lamina and the surrounding extracellular matrix [148].
Simultaneous to the controlled digestion of the extra-cellular
scaffolding, a burst of mitotic activity of smooth muscle cells
and endothelial cells is initiated, resulting in an outward re-
modeling and a subsequent larger cross sectional area of the
collateral artery. The enhanced cross sectional diameter causes
the blood flow velocity and shear stress to normalize. Hence,
the arteriogenic process is self-limiting after collateral arteries
reach a sufficiently large diameter. Further maturation of the
vessel occurs through the orderly arrangement of smoothmus-
cle cells in circular layers, establishment of cell-cell contacts
and the synthesis of elastin and collagen [150].
However, despite the extensive pre-existing collateral net-
work (and thereby possible opportunities for arteriogenic re-
pair) in the human body, most molecular neovascularization
imaging research to date has focused on angiogenesis, leaving
molecular arteriogenesis imaging largely overlooked. This is
not particularly useful, as arteriogenesis is more capable of
restoring tissue blood supply than angiogenesis [15, 151], as
collateral vessels have the capacity to carry a larger volume of
blood than sprouting capillary networks [152]. At present,
determining precise morphology is still dependent on post
mortem angiography, as some collateral arteries (i.e. collateral
arteries in the subendocardial plexus of the left ventricle) are
Fig. 2 Key features in angiogenic and arteriogenic vessel growth. Both
processes share their dependency on macrophage guided, controlled
extracellular matrix and vessel scaffold degradation. Nevertheless, both
the initial stimulus and the outcome differ significantly between both
processes. *Established in pre-clinical models. Modified from
Buschmann and Schaper, 1999, Physiology [145]
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rather poorly represented in clinical angiography [15].
Molecular tracers for arteriogenesis imaging are also lacking
despite the identification of a fairly extensive set of molecular
circuits that are perturbed [150].
Radiotracer imaging of arteriogenesis in models
for myocardial ischemia
Despite the lack of specific radiotracers for arteriogenesis,
there are studies in which histological findings to indicate
ongoing arteriogenesis were supported by nuclear imaging
(and vice versa), both in the context of MI as well as PVD.
As already alluded to in the BPerfusion tracers in neovascular-
ization research^ section in this review, perfusion tracers for
PET and SPECT can be used for this purpose.
Li et al. employed gene therapy using a plasmid-encoding,
human-platelet-derived endothelial cell growth factor (PD-
ECGF) cDNA in a dog chronic myocardial ischemia model.
A double immunohistochemical staining for von Willebrand
factor and α smooth-muscle actin (αSMA) demonstrated that
angiogenesis and arteriogenesis occurred. These findings
were accompanied by enhanced myocardial blood flow
2 weeks after induction of gene therapy, as indicated by N13-
ammonia PET imaging [153]. In a different study, Zuo et al.
subjected pigs to coronary artery ligation and subsequent
intramyocardial administration of a recombinant adeno-
associated virus construct coding CD151 (a tetraspanin super-
family protein). Using N13-ammonia PET, they found signif-
icantly enhanced regional myocardial perfusion 8 weeks after
viral transduction, which was accompanied by a marked in-
crease in capillary (indicated by von Willebrand staining) and
arteriolar density (indicated by αSMA staining) [154].
Furthermore, in rats subjected to coronary artery ligation,
Kainuma et al. showed that combined treatment of the ische-
mic myocardium with skeletal myoblast cell-sheet plus an
omentum-flap resulted in a greater amount of functionally
(CD31+/Lectin+) and structurally (CD31+/αSMA+) mature
blood vessels 4 weeks after treatment. Additionally, N13-
ammonia PET showed better global coronary flow reserve in
the group receiving this combined treatment [155].
While the majority of studies linking enhanced myocardial
blood flow to enhanced arteriogenesis (in combination with
angiogenesis) employed N13-ammonia (getting metabolically
trapped in viable tissue) PET perfusion imaging, there are also
studies that used SPECT imaging to link augmented myocar-
dial perfusion to enhanced arteriogenesis.
Crottogini et al. investigated the effect of intramyocardial
plasmid-mediated human VEGF165 gene transfer on the pro-
liferation of vessels with smooth muscle in a pig model of
myocardial ischemia. Using 99mTc-sestamibi SPECT imaging,
they reported enhancedmyocardial perfusion accompanied by
a significant increase in small sized collateral vessels com-
pared to placebo treated pigs. However, angiographic quanti-
fication of collateral development using the Rentrop score
failed to indicate a significant difference between the groups
[156]. In a different study by the same group, Janavel et al.
investigated the effect of VEGF gene transfer on the evolution
of experimental myocardial infarction in adult sheep. They
found an increase in angiogenesis (7 days after coronary artery
ligation) and arteriogenesis (10 and 15 days after coronary
artery ligation). Additionally, using 99mTc-sestamibi SPECT,
they found increased resting myocardial perfusion in VEGF-
treated sheep 15 days after coronary artery ligation [157].
Although several studies relate enhanced perfusion and
smooth muscle positivity to increased arteriogenesis, caution
has to be taken when using this ambiguous term. Both the
maturation of angiogenic vessels as well as collateral forma-
tion are coined arteriogenesis despite the difference in impact
they have on perfusion recovery. While both cause enhanced
smooth muscle detectability, collateral formation is more po-
tent to drive perfusion. Hence, ascribing perfusion recovery to
collateral formation requires more than showing an increase in
smooth muscle positivity. Validation of nuclear perfusion im-
aging with angiography (using the Rentrop scoring index) will
likely provide a better insight into whether perfusion recovery
is caused by maturation of angiogenic vessel or collateral for-
mation. For example, in a Yorkshire swine ameroid contrictor
Fig. 3 Mechanism of
arteriogenesis. Increased shear
stress over pre-existing collateral
arterioles triggers a macrophage
guided outward remodeling that
results in the (partial) restoration
of perfusion. Modified from
Schirmer et al., 2009, Heart [146]
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model, Mack et al. linked significant 99mTc-sestamibi SPECT
perfusion recovery in VEGF121 adenovector injected animals
to significantly enhanced Rentrop scores (ex vivo coronary
angiography) compared to control animals. However, no
αSMA staining was performed [158]. In the same pig myo-
cardial ischemia model, several other studies reported en-
hanced collateralization and perfusion after therapeutic stim-
ulation, although no nuclear perfusion imaging was per-
formed. For example, in a pig ameroid contrictor model, Tio
et al. showed enhanced myocardial perfusion (indicated by
colored microspheres), in animals intramyocardially injected
with a VEGF165 -encoding DNA containing plasmid.
Enhanced perfusion at maximal vasodilation (adenosine)
was accompanied by an increased Rentrop score compared
to control animals [159]. In a similar model, Sato et al. inves-
tigated the effect of intracoronary administration of FGF2.
Using angiography, they found significant improvement in
collateralization (assessed by Rentrop scoring), which was
supported by enhanced perfusion (microspheres and MRI)
and function (MRI) [160]. More evidence on the
collateralization enhancing effects of FGF2 was gathered by
Laham et al., also in a pig model of myocardial ischemia.
Using angiography, they found enhanced collateralization
(Rentrop scoring). Additionally, improved myocardial perfu-
sion (microspheres andMRI) and function (MRI) in the ische-
mic territory were found. Moreover, histological evidence of
increased myocardial vascularity was reported [161].
Radiotracer imaging of arteriogenesis in models
of peripheral vascular disease
Stacy et al. investigated serial changes in lower extremity
arteriogenesis and muscle perfusion in a pig model for PVD
[162]. Significant increases in collateral artery formation in
the biceps femoris and semimembranosus muscle area were
shown using CT angiography 4 weeks after ligation. They
concluded that arteriogenesis within the semimembranosus
and biceps femoris presumably resulted in improved down-
stream perfusion, which was quantified using Tl201 SPECT
and validated by postmortem gamma-counting 4 weeks after
induction of hindlimb ischemia.
More recently, our own group used 99mTc-sestamibi in a
mouse model for PVD to show that perfusion recovery
through arteriogenesis after femoral artery ligation appears
to happen much faster than suggested by standard laser-
Doppler perfusion imaging. Perfusion in the ligated hind limb
restored to levels comparable to the control limb on day 7 after
ligation surgery and was accompanied by a significant in-
crease in collateral artery diameter (αSMA). Additionally,
99mTc-pyrophosphate was used to indicate muscular damage.
Peak uptake of 99mTc-pyrophosphate was found 3 days after
femoral artery ligation, which recovered to baseline levels
14 days after surgery. The 99mTc-pyrophosphate data was
further invigorated by histological findings showing peak
monocyte/macrophage infiltration (CD68 staining) and DNA
fragmentation (TUNEL staining) on day 3 post femoral artery
ligation [163].
Developing candidate tracers for arteriogenesis
imaging
Molecular radiotracers for imaging the arteriogenic process
are lacking despite the fact that there is no scarcity in theoretic
targets. Due to the larger diameters of collaterals, classic, non-
nuclear imaging (i.e. microspheres and angiography) has been
used for detection and quantification. However, these methods
are restricted to late stage arteriogenesis and lack sensitivity or
the quantitative capacity compared to nuclear imaging tech-
niques such as SPECT or PET. Early detection of
arteriogenesis through radiotracer imaging might be a valu-
able diagnostic with therapeutic or prognostic implications.
As growing collateral arteries are hallmarked by the upregu-
lation of adhesion molecules and subsequent invasion of
monocytes (followed by T-lymphocytes) which in turn are a
rich source of different cytokines [164], there is a variety of
mechanisms that can be targeted through radiotracer imaging.
Although there is definitely an inflammatory component in-
volved in the arteriogenic process [165, 166], for example the
MCP-1 pathway that recruits monocytes to areas of collateral
artery development [167], applying ligands that bind to in-
flammatory targets might not be suitable for operating in a
transient inflammatory environment.
Designing tracers for arteriogenesis imaging requires suit-
able targets that have the potential to be labeled with a radio-
tracer (e.g. through attachment of a chelating agent).
Furthermore, a meaningful animal model both for cardiac
arteriogenesis as well as arteriogenesis in PVD, and a sensitive
and specific imaging readout are needed. To study
arteriogenesis in the setting of PVD, we have been using a
mouse [163] and rat [149] hindlimb model that are well
established models of collateral formation. For the cardiac
arteriogenesis, we have been using a mouse infarct model
[168, 169], although the distinction between angiogenesis
and arteriogenesis cannot be clearly made. Furthermore, a
porcine model of chronic myocardial ischemia by an ameroid
contrictor has been used in combination with whole mount
cryomicrotome imaging to unambiguously show collateral
development [165].
Targets we have been chasing include an ICAM-1 anti-
body, chemokines such as CXCL1, and other ligands that bind
to chemokines (e.g. Evasin3, binding to CXCL1). When de-
signing tracers, we have focused on a double-labeling ap-
proach (i.e. fluorescent tag, as well as the ability to attach a
radioisotope through a chelator).We opted for this approach to
enable correct spatiotemporal presentation of target binding of
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our tracers. While the fluorescent tag facilitates the option to
perform fluorescence microscopy or high resolution two-
photon laser scanning microscopy (TPLSM), the chelator pro-
vides the option for radiotracer imaging. Subsequent chasing
experiments with non-radiolabeled agents could serve as indi-
cation for target binding specificity.
So far, these novel tracers, however, proved to be ineffec-
tive as imaging agents. Reasons for this failure might be that
most targets reside at endothelial cells, are expressed at low
intensity and exposed to a high flow circulatory environment.
Nevertheless, while the target should be abundantly expressed
in the area of collateralization, it should not (or only margin-
ally) be expressed in non-specific areas. The monoclonal anti
ICAM antibody we tested in vivo appeared to bind to consti-
tutively expressed ICAM-1 on the endothelial lining in every
vessel, thereby making it impossible to distinguish specific
binding patterns. Moreover, it is conceivable that an
arteriogenesis specific tracer should engage in polyvalent
binding before being able to overcome the high shear stress
in the area of collateralization.
Conclusion
Advances in radiotracer imaging are made through continu-
ously improving camera hard- and software as well as through
the development of new radiotracers with favorable imaging
characteristics. In this review, we discussed the role of perfu-
sion tracers and provided an extensive overview of pre-
clinical research into radiotracer imaging of angiogenesis
and arteriogenesis in the context of MI and PVD.
Abundant pre-clinical research has resulted in the identifi-
cation and development of angiogenesis tracers, while the
development of specific arteriogenesis tracers remains largely
overlooked. So far, perfusion tracers have been used to indi-
cate enhanced perfusion through arteriogenesis (in combina-
tion with angiogenesis). Currently, only a few angiogenesis
(targeting the αvβ3 integrin) tracers have found their way to
the clinic and broad-scale implementation of specific angio-
genesis and arteriogenesis imaging in MI and PVD patients is
still lacking. Future research should therefore focus on im-
proving the translation of neovascularization tracers into the
clinic, especially in the case of arteriogenesis. However, as
illustrated in the last section, designing a tracer, specific for
arteriogenesis imaging is not easy. When designing an
arteriogenesis tracer, it is important to keep in mind the high
shear stress environment that has to be overcome (potentially
requiring polyvalent binding), as well as the notion that in-
flammatory factors might not operate well within a transient
inflammatory setting. Clinical implementation of specific an-
giogenesis and arteriogenesis imaging can aid tailored therapy
and would be a huge asset to MI and PVD patient risk
stratification.
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